Evidence map›Paper›PMID 41144758›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

tRNA-Derived Fragment tRF-22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma.

Ling Pan, Xin Qin, Li Gong, Haining Liu, Bo Cheng, Jing Wang, Yajie Hu, Lingxing Zeng, Yiping Wang, Qingxu Song and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ling PanDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.ORCID https://orcid.org/0000-0001-8881-9499
Xin QinDepartment of Urology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Li GongDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Haining LiuDepartment of Organ Transplantation, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Bo ChengDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Jing WangDepartment of Urologic Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
Yajie HuDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Lingxing ZengState Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Yiping WangDepartment of Urology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Qingxu SongDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Yufeng ChengDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.ORCID https://orcid.org/0000-0001-8342-5802

Funding

BeiGene Foundation 6010121159Central Guiding Local Science and Technology Development Fund Projects YDZX2023026Central Universities 2022JC010National Natural Science Foundation of China 82172664National Natural Science Foundation of China 82203455National Natural Science Foundation of China 82403892National Natural Science Foundation of China U24A20732Natural Science Foundation of Shandong Province ZR2021LSW020Natural Science Foundation of Shandong Province ZR2022QH242Taishan Scholar Foundation of Shandong Province ts20190973
6 · The paper itself

Abstract

Small proportions of patients with esophageal squamous cell carcinoma (ESCC) benefit from immune checkpoint blockade therapy, making it urgent to identify factors that limit its effectiveness. It is found that tRF-22, a small RNA derived from tRNA

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMiceMyeloid-Derived Suppressor CellsTranscription FactorsTransforming Growth Factor beta2Tripartite Motif ProteinsTumor MicroenvironmentUbiquitinationUbiquitin-Protein LigasesTranscription FactorsTransforming Growth Factor beta2TRIM25 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligasesesophageal squamous cell carcinomahnRNPABimmunosuppressive tumor microenvironmentimmunotherapytRF‐22

Identifiers

PMID41144758
PMCPMC12767015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.